Berkeley Heights, NJ - June 20, 2005 -
Genta Incorporated (Nasdaq: GNTA) today announced that the Company
will provide an audio webcast its 2005 Annual Meeting of
Shareholders. The meeting will be held on Thursday, June 23,
2005, at 11:00 am EST, at The Hotel Westminster in Livingston, NJ.
A live audio webcast of the presentation can be accessed through
Genta's Investor Relations site at:
http://www.genta.com/genta/InvestorRelation/events.html
. A replay will be available approximately 24 hours following
the presentation and will be available for 30 days thereafter.
The conference call can be accessed as follows:
U.S./Canada: Dial (800) 769-8320 (reference Genta
Shareholder Meeting)
International: Dial (416) 695-6120 (reference Genta
Shareholder Meeting)
Shareholders wishing to attend the meeting may call the hotel at
973-533-0600 for directions and information.
About Genta
Genta Incorporated is a biopharmaceutical company with a
diversified product portfolio that is focused on delivering
innovative products for the treatment of patients with cancer. The
Company's research platform is anchored by two major programs that
center on oligonucleotides (RNA and DNA-based medicines) and small
molecules. Genasense® (oblimersen sodium) Injection, the
Company's lead compound from its oligonucleotide program is
currently undergoing late-stage, Phase 3 clinical testing.
The leading drug in Genta's small molecule program is Ganite®
(gallium nitrate injection), which the Company is exclusively
marketing in the U.S. for treatment of patients with cancer-related
hypercalcemia that is resistant to hydration. For more
information about Genta, please visit our website at:
http://www.genta.com/
.
This press release and the webcast to follow contain
forward-looking statements with respect to business conducted by
Genta Incorporated. By their nature, forward-looking statements and
forecasts involve risks and uncertainties because they relate to
events and depend on circumstances that will occur in the future.
There are a number of factors that could cause actual results and
developments to differ materially. For a discussion of those risks
and uncertainties, please see the Company's Annual Report/Form 10-K
for 2004.
SOURCE: Genta Incorporated
